SEC For	rm 4 FORM 4	4		STATI	ES S	ECU	RITIES	S AND E	EXCHAN	GE CO	MMIS	SION				
					TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OM	OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						JT OF CHANGES IN BENEFICIAL OWNERSHIP pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1 Namo a	nd Address of	Penorting Percon*						er or Trading		1940	5. Re	elationship of	f Reporting Per	son(s) to Issu	er	
1. Name and Address of Reporting Person [*] Grant Grady_III					<u>Aptevo Therapeutics Inc.</u> [APVO]							ck all applica	able)	10% Ov	10% Owner	
(Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/27/2020							Officer (below)	(give title	Other (s below)	pecity	
2401 4TH AVENUE, SUITE 1050												6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SEATTLE WA			98121								1 '	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Zip)															
		Ta	able I - Non-	Deriva	tive S	ecurit	ties Acc	quired, Di	sposed of	f, or Ben	eficially	Owned				
Date					action 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) d Disposed Of (D) (Instr. 3, 4		(A) or 3, 4 and 5]	Beneficial Owned Fo	s For Ily (D) bllowing (I) (I	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 an	on(s)		(Instr. 4)	
			Table II - D (e						posed of, convertib			Dwned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		nber of itive ities red (A) or sed of str. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$41.16 ⁽¹⁾	07/27/2020		D			1,339 ⁽¹⁾	(2)	08/03/2026	Common Stock	1,339 ⁽¹⁾	(3)	0	D		
Stock Option (right to buy)	\$30.1 ⁽¹⁾	07/27/2020		D			892 ⁽¹⁾	(4)	06/01/2027	Common Stock	892 ⁽¹⁾	(3)	0	D		
Stock Option (right to buy)	\$76.86 ⁽¹⁾	07/27/2020		D			1,785 ⁽¹⁾	(5)	06/01/2028	Common Stock	1,785(1)	(3)	0	D		
Stock Option (right to buy)	\$8.56	07/27/2020		A		1,322		(6)	07/26/2030	Common Stock	1,322	(3)	1,322	D		
Stock Option (right to buy)	\$8.56	07/27/2020		A		170		(7)	07/26/2030	Common Stock	170	(3)	170	D		

Explanation of Responses:

1. Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020.

2. These options vested in three approximately equal annual installments beginning on August 3, 2017.

3. In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4.

4. These options vested in three approximately equal annual installments beginning on June 1, 2018.

5. These options provide for vesting in three approximately equal annual installments beginning on May 31, 2019. Prior to July 27, 2020, all but 595 shares of the issuer's common stock underlying this stock option had vested.

6. These options vest in full on the one year anniversary of the date of grant.

7. These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant.

/s/ Carl A. Valenstein, attorneyin-fact 07/29/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.